NICE positive recommendation for Opdivo + Yervoy to treat malignant pleural mesothelioma
The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document (FAD) recommending the combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM), in England and Wales
This treatment combination is the first immunotherapy in over ten years to be made available via the NHS for the treatment of untreated, unresectable MPM.
MPM is a type of mesothelioma caused primarily by exposure to asbestos. It affects the chest and lungs and is often diagnosed late, giving patients an average of less than a year’s survival without treatment.
Related news and insights
Bristol Myers Squibb announced new results from the Phase III DAYBREAK open-label extension trial, demonstrating the long-term efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis (MS).
SpringWorks Therapeutics, Inc. announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for nirogacestat, an oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors
Ironwood Pharmaceuticals, Inc. a GI-focused healthcare company, announced positive topline results from its pivotal Phase III STARS trial, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in reducing parenteral support (PS) dependency in adult patients with short bowel syndrome with intestinal failure (SBS-IF)